Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Integrative Approaches to Cancer Survivorship: Project 3
Developing an Integrative Intervention for Breast Cancer Survivorship
Status: Enrolling
Updated:  12/31/1969
University of California, San Francisco, Osher Center for Integrative Medicine
355
mi
from 91732
San Francisco, CA
Integrative Approaches to Cancer Survivorship: Project 3
Developing an Integrative Intervention for Breast Cancer Survivorship
Status: Enrolling
Updated: 12/31/1969
University of California, San Francisco, Osher Center for Integrative Medicine
355
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Banner MD Anderson Cancer Center
361
mi
from 91732
Gilbert, AZ
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Banner MD Anderson Cancer Center
361
mi
from 91732
Gilbert, AZ
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology-Oncology Clinic
1589
mi
from 91732
Baton Rouge, LA
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology-Oncology Clinic
1589
mi
from 91732
Baton Rouge, LA
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Allina Health, Virginia Piper Cancer Institute
1510
mi
from 91732
Minneapolis, MN
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Allina Health, Virginia Piper Cancer Institute
1510
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated:  12/31/1969
San Juan Oncology Associates
580
mi
from 91732
Farmington, NM
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated: 12/31/1969
San Juan Oncology Associates
580
mi
from 91732
Farmington, NM
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Allegheny General Hospital
2118
mi
from 91732
Pittsburgh, PA
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Allegheny General Hospital
2118
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northwest Medical Specialties
933
mi
from 91732
Lakewood, WA
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northwest Medical Specialties
933
mi
from 91732
Lakewood, WA
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Fundación CENIT para la Investigación en Neurociencias
6112
mi
from 91732
Buenos Aires,
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Fundación CENIT para la Investigación en Neurociencias
6112
mi
from 91732
Buenos Aires,
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated:  12/31/1969
CBCC Global Research Inc. at Comprehensive Blood and Cancer Center
106
mi
from 91732
Bakersfield, CA
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated: 12/31/1969
CBCC Global Research Inc. at Comprehensive Blood and Cancer Center
106
mi
from 91732
Bakersfield, CA
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Maryland Oncology Hematology, P.A.
2274
mi
from 91732
Rockville, MD
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Maryland Oncology Hematology, P.A.
2274
mi
from 91732
Rockville, MD
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated:  12/31/1969
John Theurer Cancer Center at the Hackensack University Medical Center
2430
mi
from 91732
Hackensack, NJ
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated: 12/31/1969
John Theurer Cancer Center at the Hackensack University Medical Center
2430
mi
from 91732
Hackensack, NJ
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Westchester Medical Center Cancer Institute
2442
mi
from 91732
Hawthorne, NY
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Westchester Medical Center Cancer Institute
2442
mi
from 91732
Hawthorne, NY
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Levine Cancer Institute
2102
mi
from 91732
Charlotte, NC
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Levine Cancer Institute
2102
mi
from 91732
Charlotte, NC
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Tech University HSC
689
mi
from 91732
El Paso, TX
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Tech University HSC
689
mi
from 91732
El Paso, TX
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of New Mexico Comprehensive Cancer Center
649
mi
from 91732
Albuquerque, NM
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of New Mexico Comprehensive Cancer Center
649
mi
from 91732
Albuquerque, NM
Click here to add this to my saved trials
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
A Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
1654
mi
from 91732
Madison, WI
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
A Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Research Center
24
mi
from 91732
Anaheim, CA
Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Research Center
24
mi
from 91732
Anaheim, CA
Click here to add this to my saved trials
Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
Phase II Trial of Gemcitabine and Genistein in Metastatic Breast Cancer Patients With Biomarker Assays
Status: Enrolling
Updated:  12/31/1969
Barbara Ann Karmanos Cancer Institute
1966
mi
from 91732
Detroit, MI
Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
Phase II Trial of Gemcitabine and Genistein in Metastatic Breast Cancer Patients With Biomarker Assays
Status: Enrolling
Updated: 12/31/1969
Barbara Ann Karmanos Cancer Institute
1966
mi
from 91732
Detroit, MI
Click here to add this to my saved trials
Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC
A Phase II Study Of Pembrolizumab In Combination With Palliative Radiotherapy For Metastatic Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC
A Phase II Study Of Pembrolizumab In Combination With Palliative Radiotherapy For Metastatic Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer
Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Sibley Memorial Hospital
2281
mi
from 91732
Washington,
Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer
Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Sibley Memorial Hospital
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
Development of Real-time Image-guided Radiotherapy
Development of Real-time Image-guided Radiotherapy
Status: Enrolling
Updated:  12/31/1969
Temple University Hospital
2375
mi
from 91732
Philadelphia, PA
Development of Real-time Image-guided Radiotherapy
Development of Real-time Image-guided Radiotherapy
Status: Enrolling
Updated: 12/31/1969
Temple University Hospital
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)
Qualitative and Quantitative Analysis of Cystic Breast Masses by Contrast Enhanced Ultrasound: Is Biopsy Necessary?
Status: Enrolling
Updated:  12/31/1969
USC Department of Radiology
10
mi
from 91732
Los Angeles, CA
Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)
Qualitative and Quantitative Analysis of Cystic Breast Masses by Contrast Enhanced Ultrasound: Is Biopsy Necessary?
Status: Enrolling
Updated: 12/31/1969
USC Department of Radiology
10
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function
The Effects of Anthracycline-based Chemotherapy on Spontaneous Baroreflex Sensitivity, Carotid Artery Stiffness, and Endothelial-dependent Vascular Function.
Status: Enrolling
Updated:  12/31/1969
Lafene Health Center
mi
from 91732
Manhattan, KA
The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function
The Effects of Anthracycline-based Chemotherapy on Spontaneous Baroreflex Sensitivity, Carotid Artery Stiffness, and Endothelial-dependent Vascular Function.
Status: Enrolling
Updated: 12/31/1969
Lafene Health Center
mi
from 91732
Manhattan, KA
Click here to add this to my saved trials
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
Autotransplantation and Her 2 Neu Antibody Immunotherapy in Advanced Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
2578
mi
from 91732
Boston, MA
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
Autotransplantation and Her 2 Neu Antibody Immunotherapy in Advanced Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
Autotransplantation and Her 2 Neu Antibody Immunotherapy in Advanced Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center
2430
mi
from 91732
Hackensack, NJ
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
Autotransplantation and Her 2 Neu Antibody Immunotherapy in Advanced Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
2430
mi
from 91732
Hackensack, NJ
Click here to add this to my saved trials
Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer
A Pilot Study Evaluating Surrogates of Response to Short Term Oral Suberoylanilide Hydroxamic Acid (SAHA) in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
2302
mi
from 91732
Baltimore, MD
Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer
A Pilot Study Evaluating Surrogates of Response to Short Term Oral Suberoylanilide Hydroxamic Acid (SAHA) in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
2302
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM
A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction
Status: Enrolling
Updated:  12/31/1969
Northwestern University Medical Center
1730
mi
from 91732
Chicago, IL
Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM
A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction
Status: Enrolling
Updated: 12/31/1969
Northwestern University Medical Center
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM
A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction
Status: Enrolling
Updated:  12/31/1969
NorthShore Health Systems
mi
from 91732
Evanston, IL
Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM
A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction
Status: Enrolling
Updated: 12/31/1969
NorthShore Health Systems
mi
from 91732
Evanston, IL
Click here to add this to my saved trials
Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM
A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction
Status: Enrolling
Updated:  12/31/1969
Louisiana State Health Science Center
mi
from 91732
New Orleans, LA
Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM
A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction
Status: Enrolling
Updated: 12/31/1969
Louisiana State Health Science Center
mi
from 91732
New Orleans, LA
Click here to add this to my saved trials
Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM
A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM
A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM
A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction
Status: Enrolling
Updated:  12/31/1969
Faulkner Brigham & Women's Hospital
mi
from 91732
Jamaica Plain, MA
Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM
A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction
Status: Enrolling
Updated: 12/31/1969
Faulkner Brigham & Women's Hospital
mi
from 91732
Jamaica Plain, MA
Click here to add this to my saved trials
Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM
A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction
Status: Enrolling
Updated:  12/31/1969
New York University Langone Medical Center
2434
mi
from 91732
New York, NY
Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM
A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction
Status: Enrolling
Updated: 12/31/1969
New York University Langone Medical Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM
A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction
Status: Enrolling
Updated:  12/31/1969
Harris Methodist Southlake Hospital
mi
from 91732
Fort Worth, TX
Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM
A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction
Status: Enrolling
Updated: 12/31/1969
Harris Methodist Southlake Hospital
mi
from 91732
Fort Worth, TX
Click here to add this to my saved trials
Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer
Dose Finding and Efficacy Evaluation of DOXIL (Doxorubicin HCL Liposome Injection) in Combination With Abraxane (Abraxane) in Patients With Metastatic Breast Cancer (MBC) [Phase I and II]
Status: Enrolling
Updated:  12/31/1969
Clinical Trials Research Unit, West Virginia University
2122
mi
from 91732
Morgantown, WV
Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer
Dose Finding and Efficacy Evaluation of DOXIL (Doxorubicin HCL Liposome Injection) in Combination With Abraxane (Abraxane) in Patients With Metastatic Breast Cancer (MBC) [Phase I and II]
Status: Enrolling
Updated: 12/31/1969
Clinical Trials Research Unit, West Virginia University
2122
mi
from 91732
Morgantown, WV
Click here to add this to my saved trials
Eniluracil Hand Foot Syndrome
A Pilot Study of Eniluracil Containing Ointment for Prevention of Hand Foot Syndrome (HRS) Following Capecitabine (Xeloda)
Status: Enrolling
Updated:  12/31/1969
Clinical Trials Research Unit, West Virginia University
2122
mi
from 91732
Morgantown, WV
Eniluracil Hand Foot Syndrome
A Pilot Study of Eniluracil Containing Ointment for Prevention of Hand Foot Syndrome (HRS) Following Capecitabine (Xeloda)
Status: Enrolling
Updated: 12/31/1969
Clinical Trials Research Unit, West Virginia University
2122
mi
from 91732
Morgantown, WV
Click here to add this to my saved trials
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer
Pilot Study Of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Rebecca and John Moores UCSD Cancer Center
93
mi
from 91732
La Jolla, CA
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer
Pilot Study Of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Rebecca and John Moores UCSD Cancer Center
93
mi
from 91732
La Jolla, CA
Click here to add this to my saved trials
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
1730
mi
from 91732
Chicago, IL
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
Status: Enrolling
Updated:  12/31/1969
Northwestern University- Lake Forest Hospital
1723
mi
from 91732
Lake Forest, IL
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
Status: Enrolling
Updated: 12/31/1969
Northwestern University- Lake Forest Hospital
1723
mi
from 91732
Lake Forest, IL
Click here to add this to my saved trials
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
356
mi
from 91732
Scottsdale, AZ
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
356
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
1728
mi
from 91732
Chicago, IL
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
1728
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from 91732
Westwood, KA
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from 91732
Westwood, KA
Click here to add this to my saved trials
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
1522
mi
from 91732
Rochester, MN
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
1522
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from 91732
Lebanon, NH
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from 91732
Lebanon, NH
Click here to add this to my saved trials
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
2436
mi
from 91732
Bronx, NY
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
2436
mi
from 91732
Bronx, NY
Click here to add this to my saved trials
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
2433
mi
from 91732
New York, NY
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
2433
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
1960
mi
from 91732
Columbus, OH
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
1960
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
1763
mi
from 91732
Nashville, TN
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
1763
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
Health Benefits of Expressive Writing: Study One
Expressive Writing Among Chinese Breast Cancer Survivors: Study One
Status: Enrolling
Updated:  12/31/1969
Herald Cancer Association
4
mi
from 91732
Los Angeles, CA
Health Benefits of Expressive Writing: Study One
Expressive Writing Among Chinese Breast Cancer Survivors: Study One
Status: Enrolling
Updated: 12/31/1969
Herald Cancer Association
4
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Health Benefits of Expressive Writing: Study One
Expressive Writing Among Chinese Breast Cancer Survivors: Study One
Status: Enrolling
Updated:  12/31/1969
University of Houston
1355
mi
from 91732
Houston, TX
Health Benefits of Expressive Writing: Study One
Expressive Writing Among Chinese Breast Cancer Survivors: Study One
Status: Enrolling
Updated: 12/31/1969
University of Houston
1355
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Tracking Physical Activity Throughout Chemotherapy for Breast Cancer
Tracking Physical Activity Throughout Chemotherapy for Breast Cancer
Status: Enrolling
Updated:  12/31/1969
The University of California, San Diego
95
mi
from 91732
La Jolla, CA
Tracking Physical Activity Throughout Chemotherapy for Breast Cancer
Tracking Physical Activity Throughout Chemotherapy for Breast Cancer
Status: Enrolling
Updated: 12/31/1969
The University of California, San Diego
95
mi
from 91732
La Jolla, CA
Click here to add this to my saved trials